In April 2018, Tango Biosciences received a R41 award from NIH. The goals of the grant are to generate two-site capable affinity reagents through MegaSTAR to two sets of targets. One set represents biomarkers of colorectal cancer and myocardial infarction. MegaSTAR reagents will be benchmarked against existing commercial sandwich reagents, and the performance metrics (i.e., intra-assay and inter-assay precision, linearity, sensitivity) will be evaluated and compared through ELISA. The second set of targets is a family of membrane proteins. Successful production of specific affinity reagents to the ectodomains will showcase the potential of MegaSTAR to generate reagents to challenging targets.
NIH STTR award
More News and Events
-
New Phase II SBIR Grant
Tango Biosciences has been awarded a phase II SBIR grant by the National Institutes of Health (NIH) in September 2026. This award will support the continued development of Tango Biosciences’ phage display platform to discover phosphobodies, antibody-like molecules that recognize distinct phosphorylated targets with unprecedented precision and specificity. The platform and affinity reagents generated in […]
-
News
NIH Awards New Phase I SBIR Grant
The National Institute of Health (NIH) awarded a phase I SBIR grant to Tango Biosciences in August 2026. This award will support the development of Tango Biosciences’ phage display platform to identify peptide tools that act as proximity inducing modalities (e.g., molecular glues). The program will generate proof-of-concept data for driving proximity of two protein […]
-
Tango Biosciences Celebrates 10 Years of Discovery
This year Tango Biosciences celebrates their ten-year anniversary, a milestone that resonates with scientific innovation and a sustained commitment to solving complex challenges in drug discovery and diagnostics. Visionary founders Dr. Brian Kay and Michael Scholle recently sat down to take a deep dive into the company’s incredible journey. They revealed an origin story that perfectly […]